Last quarter (Q2 2022), Genscript Biotech's total revenue was $―, a decrease of ― from the same quarter last year. In Q2, Genscript Biotech's net income was $―. See Genscript Biotech’s key income statements, including revenue, expenses, profit, and income.

Income Statement	TTM	Dec 21	Dec 20	Dec 19	Dec 18	Dec 17
Total Revenue	-	$ 511.06M	$ 390.33M	$ 273.35M	$ 231.02M	$ 152.65M
Cost of Revenue	-	$ 207.58M	$ 134.95M	$ 93.06M	$ 72.48M	$ 48.06M
Gross Profit	-	$ 303.48M	$ 255.38M	$ 180.29M	$ 158.54M	$ 104.59M
Operating Expense	-	$ 651.73M	$ 447.89M	$ 303.67M	$ 149.83M	$ 60.73M
Operating Income	-	$ -348.25M	$ -192.51M	$ -123.38M	$ 8.71M	$ 43.86M
Net Non Operating Interest Income Expense	-	$ 407.00K	$ -1.13M	$ 7.57M	$ 9.95M	$ 857.00K
Other Income Expense	-	-	-	-	-	-
Pretax Income	-	$ -496.38M	$ -281.90M	$ -113.69M	$ 22.70M	$ 38.52M
Tax Provision	-	$ 4.58M	$ -477.00K	$ 3.83M	$ 1.94M	$ 11.52M
Earnings From Equity Interest Net Of Tax	-	-	-	-	-	-
Net Income Common Stockholders	-	$ -347.87M	$ -204.94M	$ -96.91M	$ 21.22M	$ 26.12M
Basic EPS	-	$ -0.17	$ -0.11	$ -0.05	$ 0.01	$ 0.02
Diluted EPS	-	$ -0.17	$ -0.11	$ -0.05	$ 0.01	$ 0.02
Basic Average Shares	-	$ 2.03B	$ 1.90B	$ 1.85B	$ 1.79B	$ 1.71B
Diluted Average Shares	-	$ 2.03B	$ 1.90B	$ 1.89B	$ 1.84B	$ 1.73B
Dividend Per Share	-	$ 0.00	$ 0.00	$ 0.00	$ 0.00	$ <0.01
Total Operating Income As Reported	-	-	-	-	-	-
Reported Normalized Basic E P S	-	-	-	-	-	-
Reported Normalized Diluted E P S	-	-	-	-	-	-
Rent Expense Supplemental	-	-	-	-	-	-
Total Expenses	-	$ 859.31M	$ 582.84M	$ 396.73M	$ 222.31M	$ 108.79M
Net Income From Continuing And Discontinued Operation	-	$ -347.87M	$ -204.94M	$ -96.91M	$ 21.22M	$ 26.12M
Normalized Income	-	$ -350.09M	$ -211.07M	$ -96.13M	$ 20.93M	$ 25.38M
Interest Expense	-	$ 2.38M	$ 1.42M	$ 781.00K	$ 52.00K	$ 0.00
EBIT	-	$ -494.00M	$ -280.48M	$ -112.91M	$ 22.75M	$ 38.52M
EBITDA	-	$ -446.22M	$ -247.59M	$ -112.91M	$ 35.69M	$ 45.52M

Currency in USD

Genscript Biotech Earnings and Revenue History

Get More with TipRanks Premium

What's Included in PREMIUM?

Make informed decisions based on Top Analysts' activity

Know what industry insiders are buying

Get actionable alerts from top Wall Street Analysts

Find out before anyone else which stock is going to shoot up

Get powerful stock screeners & detailed portfolio analysis

Subscribe Now See Plans & Pricing